Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yi'ai Fuzheng No.II Decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by Zhongnan Hospital of Wuhan University. It is primarily investigated as an adjuvant therapy for patients with advanced triple-negative breast cancer (TNBC) who are undergoing conventional treatments such as radiotherapy and chemotherapy. The decoction is designed based on the TCM principle of "Fuzheng," which aims to strengthen the body's vital energy and immune function to improve tolerance to aggressive anti-cancer therapies. Clinical studies, such as ChiCTR2300073932, evaluate its efficacy in improving tumor response rates, disease control, and survival outcomes, while also assessing its ability to mitigate treatment-related toxicities and improve the quality of life as measured by TCM syndrome scores and performance status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yi'ai Fuzheng No.II Decoction.